Executive Assistant:
Kayla Seaman
(617) 949-2179

Paris Panayiotopoulos
Operating Partner

Paris Panayiotopoulos served as President and Chief Executive Officer and a member of the Board of Directors of ARIAD Pharmaceuticals, Inc., where he led the transformation of ARIAD into a leading rare cancer company, achieving approximately a five-fold multiple in market value in one year and the acquisition by Takeda Pharmaceuticals for $5.2 billion in February 2017. 


Prior to joining ARIAD in January 2016, Mr. Panayiotopoulos served as President of EMD Serono, Inc., the North American biopharmaceutical  business of Merck KGaA, President of the Serono Research & Development Institute, and President of Merck Serono, Tokyo, Japan.


Mr. Panayiotopoulos is currently serving as Chairman of Genevant Sciences, a member of the Board of Directors of the Medicines Company and Corbus Pharmaceuticals, has served on the Boards of BIO, EFPIA and Mass Bio, and is on the Board of Advisors of the nonprofit Life Science Cares.


Prior to joining Merck KGaA, Mr. Panayiotopoulos was at Eli Lilly & Co. from 1999 to 2004. He is deeply interested in both science and business innovation and holds a combined B.Sc. in Chemistry and Management Studies from University College London and a M.Sc. from Cranfield Business School in the United Kingdom.

Clarus Board Seats